David GraylessSep 26, 2025
Sodium-dependent glucose #cotransporters (or sodium-glucose #linked transporter, SGLT) are a family of #glucoseTransporter found in the intestinal #mucosa (#enterocytes) of the #smallIntestine (SGLT1) and the #proximalTubule of the #nephron (#SGLT2 in #PCT and SGLT1 in #PST). They contribute to #renalGlucoseReabsorption. In the kidneys, 100% of the filtered glucose in the #glomerulus has to be reabsorbed along the nephron (98% in PCT, via SGLT2).
EshaHaberAug 12, 2025
Türk bilim insanları geliştirdi: Kalp hastalarına yeni tedavi umudu: Kalp yetmezliği olan ve kalbin normal ritmini kaybettiği "atriyal fibrilasyon" (AF) hastalığına sahip bireyler için Ankara Bilkent Şehir Hastanesi Kardiyoloji Bölümü Aritmi Kliniği Direktörü Prof. Dr. Serkan Topaloğlu ve Aritmi Kliniği hekimlerinden Prof. Dr. Fırat Özcan başkanlığındaki uzman ekip tarafından… https://www.eshahaber.com.tr/haber/turk-bilim-insanlari-gelistirdi-kalp-hastalarina-yeni-tedavi-umudu-248762.html?utm_source=dlvr.it&utm_medium=mastodon EshaHaber.com.tr #kalp #kalphyetmezliği #atriyalfibrilasyon #SGLT2 #tıbbiaraştırma
idw_onlineDec 12, 2023

#NVL #Leitlinien #Herzinsuffizienz #MedikamentöseTherapie #SGLT2-Inhibitoren #HFpEF

https://nachrichten.idw-online.de/2023/12/12/version-4-der-nationalen-versorgungsleitlinie-chronische-herzinsuffizienz-veroeffentlicht

Version 4 der Nationalen VersorgungsLeitlinie Chronische Herzinsuffizienz veröffentlicht

Michael Ristow, MDMar 2, 2023
#SGLT2 inhibitors mitigate #kidney tubular #metabolism and mTORC1 perturbations in type 2 #diabetes. #t2d #glucose #nephropathy https://www.jci.org/articles/view/164486 and commentary https://www.jci.org/articles/view/167700
JCI - SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes

Mohgah ElsheikhDec 12, 2022

ADA Standards of Care in #Diabetes 2023 just released. Updates include:
Emphasis on supporting up to 15% #weight loss
New #hypertension diagnosis cut-offs
Role of #SGLT2 inhibitor use in HFpEF and HFrEF
Lower #LDL goals for high-risk individuals

https://diabetesjournals.org/care/issue/46/Supplement_1

Diabetes Care

Read the current issue of Diabetes Care.

American Diabetes Association
DocCheckNov 27, 2022
#SGLT2-Inhibitoren können ein Fortschreiten von Nierenerkrankungen und akuten Nierenschäden verringern – und das unabhängig vom #Diabetes-Risiko. Das bestätigt eine aktuelle Studie.
http://docc.hk/xk9una
Empagliflozin: Geprüft auf Herz und Nieren

SGLT2-Inhibitoren können ein Fortschreiten von Nierenerkrankungen und akuten Nierenschäden verringern – und das unabhängig vom Diabetes-Risiko. Das bestätigt eine aktuelle Studie.

DocCheck Community GmbH
Silvia LeonNov 22, 2022

New meta-analysis finds #SGLT2 inhibitors are beneficial in patients with #CKD or #HF irrespective of diabetes status.

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02074-8/fulltext